{"filings":[{"id":91427,"accession_number":"0001104659-26-054942","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q1 revenue $47.8M (+16% YoY); raises FY2026 guidance to $192-196M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $47.8M (+16% YoY); commercial CGT revenue $9.1M (+26%).","Life Sciences Services revenue $26.9M (+18%); BioStorage/BioServices up 21%.","Supported 766 global clinical trials (91 Phase 3) and 21 commercial CGTs as of March 31.","FY2026 revenue guidance raised to $192M-$196M versus prior outlook.","Four BLA/MAA filings in Q1; Rocket Pharma FDA approval for KRESLADI gene therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":47798000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101497,"accession_number":"0001104659-26-022940","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport FY2025 revenue $176.2M (+12% YoY) beats guidance; FY2026 outlook $190-194M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $176.2M, up 12% YoY; Q4 revenue $45.5M, up 10% YoY.","Loss from continuing operations $34.0M; adjusted EBITDA from cont. ops -$5.8M (vs -$17.8M).","Commercial cell & gene therapy revenue $33.4M (+29% YoY); supported 760 clinical trials.","Life Sciences Services revenue $96.5M (+18%); BioStorage/BioServices up 22% to $18.4M.","Cash & investments $411.2M; repurchased 1.34M shares at avg $7.45 for $10.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117849,"accession_number":"0001104659-25-106421","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q3 revenue rises 15% to $44.2M; raises FY2025 guidance to $170-174M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 continuing ops revenue $44.2M (+15% YoY); gross margin 48.2% vs 45.5%.","Commercial Cell & Gene Therapy revenue up 36% YoY to $8.3M; supported 19 commercial therapies.","GAAP net loss attributable to common stockholders $8.9M ($0.18 loss per share) in Q3.","Adjusted EBITDA from continuing ops improved to -$0.6M from -$2.7M; cash/investments $421.3M.","Full-year 2025 revenue guidance raised to $170M-$174M from continuing operations."],"consensus_eps_estimate":null,"consensus_eps_actual":1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":130727000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134296,"accession_number":"0001104659-25-074314","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q2 revenue up 14% to $45.5M; cell & gene therapy revenue +33%; reaffirms FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $105.2M includes $117.4M gain from CRYOPDP divestiture; adjusted EBITDA improved to -$0.9M vs -$5.6M a year ago.","Life Sciences Services revenue grew 21% to $24.4M (54% of total); BioStorage/BioServices up 28%.","Commercial cell & gene therapy revenue rose 33% to $8.7M; supported 18 commercial therapies and 728 global trials.","Closed strategic partnership with DHL and divestiture of CRYOPDP on June 11, 2025; cash & investments $426M.","Reaffirmed FY2025 revenue guidance of $165M–$172M, representing 5%-10% YoY growth."],"consensus_eps_estimate":null,"consensus_eps_actual":1.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":86494000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151096,"accession_number":"0001558370-25-008613","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Cryoport completes CRYOPDP divestiture to DHL for ~$200M in cash; launches strategic partnership","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total cash consideration of ~$200M: $133M purchase price plus repayment of $77.2M in intercompany loans.","Strategic partnership with DHL Group to collaborate on life sciences supply chain, expanding APAC and EMEA reach.","Pro forma net loss from continuing ops improves: Q1 2025 loss $7.3M vs. $9.0M reported; FY2024 loss $104.5M vs. $114.8M.","Company says deal provides capital to focus on advancing Life Science Services platform and Regenerative Medicine market.","Divested entity represented $71.6M revenue in FY2024; proceeds bolster cash to $246.3M pro forma as of March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151095,"accession_number":"0001104659-25-058019","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cryoport stockholders elect all director nominees and set say-on-pay frequency at 1 year","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with votes ranging from 35.2M to 39.5M; broker non-votes 3.8M.","Ratification of Deloitte & Touche as independent auditor approved with 36.6M for, 14.5K against.","Advisory vote on named executive officer compensation approved with 31.3M for, 1.5M against.","Stockholders selected a 1-year frequency for future say-on-pay votes (31.8M votes for 1 year).","Company will hold an advisory say-on-pay vote every year until the next frequency vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151094,"accession_number":"0001104659-25-045557","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q1 revenue $41M, up 10% YoY; cell & gene therapy revenue up 33%","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Commercial Cell & Gene therapy revenue $7.2M, up 33% YoY; supported 19 commercial therapies.","Life Sciences Services revenue $22.9M (+17%); Products $18.2M (+2%); total continuing ops $41.0M.","Strategic DHL partnership; CRYOPDP divestiture expected Q2/Q3 2025, providing capital infusion.","Supported 711 global clinical trials (net +36 YoY); 79 Phase 3; six BLA/MAA filings in Q1.","Abeona's ZEVASKYN FDA-approved post-Q1; 17 more application filings anticipated in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":41040000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169986,"accession_number":"0001104659-25-029642","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cryoport sells CRYOPDP to DHL for $195M enterprise value, forms strategic partnership","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Divests CRYOPDP to DHL for total enterprise value of $195M; ~$138M cash plus repayment of ~$67M intercompany loans.","Strategic partnership formed with DHL to enhance global life sciences supply chain offerings.","Transaction expected to close in Q2 or Q3 2025, subject to regulatory approvals.","CRYOPDP handles over 600K shipments/year across 15 countries; DHL's pharma logistics revenue >EUR5B in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169985,"accession_number":"0001104659-25-020404","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport reports FY 2024 revenue $228.4M (-2% YoY); guides FY 2025 revenue $240-250M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 revenue $228.4M (down 2% YoY); Q4 revenue $59.5M (up 4% YoY).","Net loss attributable to common shareholders FY 2024 $122.8M ($2.49/sh) vs $107.6M ($2.21/sh) in FY 2023.","Commercial Cell & Gene therapy revenue grew 20% YoY to $25.9M in FY 2024.","Adjusted EBITDA negative $15.1M in FY 2024 vs negative $8.3M in FY 2023.","FY 2025 revenue guidance $240M-$250M; gross margin improved to 45.8% in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187024,"accession_number":"0001104659-24-115344","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q3 revenue flat YoY at $56.7M; services up 9%, product down 14%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders: $1.2M ($0.02/share) vs $15.3M loss ($0.31) YoY.","Life Sciences Services revenue up 9% to $39.3M; gross margin improved to 46%.","Life Sciences Products revenue down 14% to $17.4M; total gross margin 44.8%.","Full-year 2024 revenue guidance reaffirmed at $225-235M; management targets positive adjusted EBITDA in 2025.","Repurchased $175M principal of 2026 convertible notes for $154.5M; cash and short-term investments $272.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":168853000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203560,"accession_number":"0001104659-24-086344","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q2 net loss $78M including $63.8M goodwill impairment; FY24 guidance cut to $225-235M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $57.6M (+1% YoY, +5.5% sequentially); Life Sciences Services up 8%, Products down 10%.","GAAP EPS loss $1.62 (diluted); Adjusted EBITDA negative $3.8M vs. negative $1.3M a year ago.","Recorded $63.8M impairment charge related to MVE Biological Solutions goodwill write-off.","FY 2024 revenue guidance revised to $225-235M from prior range; expects positive adjusted EBITDA in 2025.","Announced $200M stock/note repurchase program; repurchased $160M of 2026 convertible notes for $141.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":112189000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203559,"accession_number":"0001104659-24-086305","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cryoport authorizes $200M repurchase program; repurchases $160M convertible notes at 11.5% discount","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $200M repurchase of common stock and/or convertible notes, effective Aug 1, 2024 through Dec 31, 2027.","Repurchasing $160M principal of 0.75% Convertible Senior Notes due 2026 at 11.5% discount ($141.6M cash).","Transactions expected to close Aug 9, 2024; $186.2M principal remains outstanding from initial $402.5M.","CEO cites strong cash position enabling debt reduction while maintaining liquidity for growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220030,"accession_number":"0001104659-24-064333","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Cryoport shareholders elect directors and approve equity plan amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; Richard Berman received 20.5M votes for and 24.0M withheld.","Ratification of Deloitte & Touche as auditor for 2024: 47.4M for, 16,304 against, 10,342 abstain.","Advisory vote on executive compensation approved: 43.4M for, 1.0M against, 53,134 abstain.","Amendment to 2018 Omnibus Equity Incentive Plan to increase authorized shares approved: 42.0M for, 2.4M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220029,"accession_number":"0001104659-24-058082","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q1 revenue falls 13% to $54.6M; net loss widens to $18.9M, adjusted EBITDA negative $7.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Life Sciences Products revenue dropped 34% YoY to $17.8M, driven by slowdown in MVE cryogenic systems demand.","Life Sciences Services revenue rose 3% to $36.8M; BioStorage/BioServices up 9%.","Net loss attributable to common stockholders was $20.9M ($0.43 per share) vs $7.6M ($0.16) a year ago.","Full-year 2024 revenue guidance reaffirmed at $242-252M; CEO cites cost-reduction initiatives including workforce cuts.","Cryoport now supports 15 commercial cell & gene therapies; 675 global clinical trials as of March 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":54592000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}